174 related articles for article (PubMed ID: 9172284)
1. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
[No Abstract] [Full Text] [Related]
2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
3. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III.
Petitou M; Lormeau JC; Choay J
Semin Thromb Hemost; 1991; 17 Suppl 2():143-6. PubMed ID: 1948084
[No Abstract] [Full Text] [Related]
4. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
5. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
[TBL] [Abstract][Full Text] [Related]
6. Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A; Petitou M
Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of heparin partial structures and their binding activities to platelets.
Koshida S; Suda Y; Sobel M; Ormsby J; Kusumoto S
Bioorg Med Chem Lett; 1999 Nov; 9(21):3127-32. PubMed ID: 10560738
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a 3-deoxy-L-iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence.
Lei PS; Duchaussoy P; Sizun P; Mallet JM; Petitou M; Sinaÿ P
Bioorg Med Chem; 1998 Aug; 6(8):1337-46. PubMed ID: 9784873
[TBL] [Abstract][Full Text] [Related]
9. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Petitou M; van Boeckel CA
Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
[TBL] [Abstract][Full Text] [Related]
10. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
11. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
Masuko S; Linhardt RJ
Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
[TBL] [Abstract][Full Text] [Related]
12. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site.
Yu G; LeBrun L; Gunay NS; Hoppensteadt D; Walenga JM; Fareed J; Linhardt RJ
Thromb Res; 2000 Dec; 100(6):549-56. PubMed ID: 11152935
[TBL] [Abstract][Full Text] [Related]
13. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Harenberg J
Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
[TBL] [Abstract][Full Text] [Related]
14. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of 1,2-cis-amino containing oligosaccharides toward biological investigation.
Manabe S
Methods Enzymol; 2010; 478():413-35. PubMed ID: 20816492
[TBL] [Abstract][Full Text] [Related]
16. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Vogel GM; Lormeau JC; Petitou M; Meuleman DG
Circ Res; 1996 Sep; 79(3):590-600. PubMed ID: 8781492
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin.
Desai UR; Petitou M; Björk I; Olson ST
J Biol Chem; 1998 Mar; 273(13):7478-87. PubMed ID: 9516447
[TBL] [Abstract][Full Text] [Related]
19. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
[TBL] [Abstract][Full Text] [Related]
20. Efficient synthesis of Idraparinux, the anticoagulant pentasaccharide.
Chen C; Yu B
Bioorg Med Chem Lett; 2009 Jul; 19(14):3875-9. PubMed ID: 19386495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
